# RTX-321 Monotherapy in Patients With HPV 16+ Tumors

> **NCT04672980** · PHASE1 · TERMINATED · sponsor: **Rubius Therapeutics** · enrollment: 9 (actual)

## Conditions studied

- Cervical Cancer
- Head and Neck Cancer
- Anal Cancer

## Interventions

- **DRUG:** RTX-321

## Key facts

- **NCT ID:** NCT04672980
- **Lead sponsor:** Rubius Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-08
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The Sponsor terminated study after dosing 3 dose groups (9 pts) and closed trial on 11/30/22. RTX-321 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared from circulation rapidly (w/in 10 min).
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672980, "RTX-321 Monotherapy in Patients With HPV 16+ Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04672980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*